{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:54:41Z","timestamp":1793361281523,"version":"4.5.0"},"reference-count":12,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,11,11]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate respiratory syncytial virus (RSV) vaccine uptake, associations, and breakthrough infection among patients with systemic autoimmune rheumatic diseases (SARDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study investigating RSV vaccination among patients with SARDs at Mass General Brigham (Boston, Massachusetts, USA). We identified all patients with SARDs who were aged \u2265 60 years and thus eligible to receive the RSV vaccine between May 2023 and February 2025. We used multivariable logistic regression to identify factors associated with RSV vaccination. Among the vaccinated, we described documented cases of laboratory-confirmed breakthrough RSV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 10,587 patients with SARDs (median age 71.7 years, 72.4% female) eligible for RSV vaccination, 1075 (10.2%) received RSV vaccination. Factors associated with higher odds of RSV vaccination included higher median census-tract household income and comorbidities, such as cancer and interstitial lung disease. Associations with lower odds of RSV vaccination included Black race, lack of previous influenza or COVID-19 vaccinations, and glucocorticoid use. RSV vaccination was not associated with specific SARD types or disease-modifying antirheumatic drugs (DMARDs), including CD20 inhibitors. Among the 1075 who were vaccinated, there were 9 (0.8%) documented cases of RSV breakthrough infection (2 hospitalizations and no deaths).<\/jats:p>\n                    <jats:p>\u00a0<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Only 10.2% of eligible patients with SARDs received RSV vaccination. Glucocorticoid users were less likely to receive RSV vaccination, whereas specific SARD types and DMARDs were not associated. Although some predictors of vaccine uptake were observed in this dataset, there are many unmeasured factors that may play a role in vaccine uptake. There were few documented breakthrough infections and no deaths. Future studies are needed to optimize RSV vaccine use and establish safety and efficacy in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0934","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:05:38Z","timestamp":1764597938000},"page":"199-205","source":"Crossref","is-referenced-by-count":2,"title":["Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases"],"prefix":"10.3899","volume":"53","author":[{"given":"Natalie A.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya S.","family":"Getachew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"O\u2019Keeffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Negron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alene A.","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-4618","authenticated-orcid":false,"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2026070105051079000_53.2.199.1","unstructured":"Centers for Disease Control and Prevention . Respiratory syncytial virus infection (RSV); 2025. Clinical overview of RSV. [Internet. Accessed March 11, 2025.] Available from: https:\/\/www.cdc.gov\/rsv\/hcp\/clinical-overview\/index.html"},{"key":"2026070105051079000_53.2.199.2","doi-asserted-by":"crossref","first-page":"152846","DOI":"10.1016\/j.semarthrit.2025.152846","article-title":"Outcomes of respiratory syncytial virus infection in patients with systemic autoimmune rheumatic diseases","volume":"75","author":"Enns","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026070105051079000_53.2.199.3","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab040"},{"key":"2026070105051079000_53.2.199.4","unstructured":"Centers for Disease Control and Prevention . Respiratory syncytial virus infection (RSV); 2024. RSV vaccine guidance for older adults. [Internet. Accessed July 7, 2025.] Available from: https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/older-adults.html#cdc_cg_special_populations_risks-recommendations"},{"key":"2026070105051079000_53.2.199.5","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s41999-024-01066-y","article-title":"Efficacy of anti-RSV vaccination in preventing respiratory syncytial virus disease and severe illness in older adults: a systematic review of randomized controlled trials","volume":"15","author":"Moreira","year":"2024","journal-title":"Eur Geriatr Med"},{"key":"2026070105051079000_53.2.199.6","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis","volume":"404","author":"Payne","year":"2025","journal-title":"Lancet"},{"key":"2026070105051079000_53.2.199.7","unstructured":"Centers for Disease Control and Prevention . Respiratory syncytial virus infection (RSV); 2024. Vaccines for older adults. [Accessed March 11, 2025.] Available from: https:\/\/www.cdc.gov\/rsv\/vaccines\/older-adults.html"},{"key":"2026070105051079000_53.2.199.8","unstructured":"Centers for Disease Control and Prevention . People who are immunocompromised; 2023. [Accessed July 7, 2025.] Available from: https:\/\/archive.cdc.gov\/www_cdc_gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-who-are-immunocompromised.html"},{"key":"2026070105051079000_53.2.199.9","doi-asserted-by":"crossref","first-page":"152846","DOI":"10.1016\/j.semarthrit.2025.152846","article-title":"Outcomes of respiratory syncytial virus infection in individuals with systemic autoimmune rheumatic disease","volume":"75","author":"Enns","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026070105051079000_53.2.199.10","doi-asserted-by":"crossref","first-page":"152108","DOI":"10.1016\/j.semarthrit.2022.152108","article-title":"Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: a cohort study","volume":"58","author":"Patel","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2026070105051079000_53.2.199.11","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2026070105051079000_53.2.199.12","doi-asserted-by":"crossref","first-page":"587517","DOI":"10.3389\/fimmu.2020.587517","article-title":"Clinical, serological, and histopathological similarities between severe COVID-19 and acute exacerbation of connective tissue disease-associated interstitial lung disease (CTD-ILD)","volume":"11","author":"Gagiannis","year":"2020","journal-title":"Front Immunol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:14:17Z","timestamp":1782908057000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,1]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.3899\/jrheum.2025-0934"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0934","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}